March 21, 2017
Concepta plc (AIM:CPT), the UK based women’s healthcare company, with its R&D centre at Colworth Park, has been unveiled as one of the best-performing shares on the AIM market in 2016.
Concepta has developed an easy-to-use product to help women with infertility issues to become pregnant. The shares listed on AIM on 26th July 2016 at 7.5p per share and during the remainder of 2016 reached a peak of 21.9p per share, representing a 192% increase. According to a recent report by Allenby Capital, Concepta’s performance has placed the company at number four in the list of top performers among the newly-admitted AIM listings in 2016.
Concepta has developed a simple product to help women with infertility issues to become pregnant. Though numerous women become pregnant without difficulty, many others plan their pregnancies, often using urine-based tests that are designed to tell them when they are at their most fertile. These might work for the average woman but, for a sizeable minority, they do not.
Concepta’s product – MyLotus – tells women exactly what their luteinising hormone levels are, even if they are lower (or higher) than the norm. Women simply perform a urine test at home and place the swab in a hand-held meter, which provides instant and highly accurate readings.
Concepta’s testing kit and app have been approved in China and the firm is expected to begin selling its products there this year. The approval process is under way in Europe, with sales expected to begin in the UK and Europe in 2017.
Keith Purdie, Business Development Director at Colworth Park, said: “This is a fantastic achievement and further establishes Concepta as a key player in the mobile health market. This success is even greater when you consider that the company’s shares only listed on the exchange in July. We at Colworth Park wish Concepta continued success.